Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Source: SeekingAlpha
2026-02-24 23:27:52 ET
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call February 24, 2026 4:30 PM EST
Company Participants
Andrew Guggenhime - President & CFO
Grant Pickering - Co-Founder, CEO & Director
James Wassil - Executive VP & COO
Mike Mullette - Chief Commercial Officer
...
Read the full article on Seeking Alpha
For further details see:
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-0.27% G/L:
$60.645 Last:
98,949 Volume:
$60.55 Open:
PCVX Latest News
April 07, 2026 04:05:00 pm
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare ConferenceMarch 18, 2026 07:34:09 pm
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateFebruary 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatePCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
